CytoDyn Inc 8-K, filed Jan 25, 2022
CytoDyn Inc. (CYDY)
About this 8-K
CytoDyn Inc filed this 8-K on January 25, 2022, reporting on events of January 13, 2022.
Items reported
- Item 3.02: Unregistered sale of equity
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
Current Report
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 25, 2022 (
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation or organization) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
(Address of principal executive offices, including zip code)
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
| None | None | None |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 3.02 Unregistered Sales of Equity Securities.
CytoDyn Inc., a Delaware corporation (the “Company”), is providing this disclosure under Item 3.02 because, as of January 19, 2022, its unregistered sales of equity securities, in the aggregate, exceeded 1% of the shares of its common stock, par value $0.001 per share (the “Common Stock”), outstanding as of January 10, 2022, the date of its last report under Item 3.02.
Exchange of Convertible Promissory Note for Shares of Common Stock
On January 19, 2022, the Company and the holder of its secured convertible promissory note issued April 2, 2021 (the “April 2 Note”), in partial satisfaction of the January maximum redemption amount, entered into an exchange agreement pursuant to which the April 2 Note was partitioned into a new note (the “January 19 Partitioned Note”) with a principal amount of $2.5 million. The outstanding balance of the April 2 Note was reduced by the January 19 Partitioned Note. The Company and the investor exchanged the January 19 Partitioned Note for approximately 5.4 million shares of common stock.
The Company relied on the exemption from registration afforded by Section 3(a)(9) of the Securities Act of 1933, as amended (the “Securities Act”) for the exchange transactions described above.
Private Placement of Common Stock and Warrants
On January 13, 2022, the Company issued in a private placement to three accredited investors a total of 1,300,000 shares of common stock, together with warrants to purchase a total of 390,000 shares of common stock at an exercise price of $1.00 per share. The warrants have a five-year term and are immediately exercisable. The securities were issued with a combined purchase price of $1.00 per fixed combination of one share of common stock and three-tenths of one warrant to purchase one share of common stock, for total gross proceeds to the Company of $1,300,000. In connection with and as additional consideration for the purchases by two related investors, the Company agreed to issue an additional 281,820 shares of common stock, effectively lowering the purchase price of 2,818,180 shares plus 704,544 warrants previously purchased by the investors from $1.10 to $1.00 per unit, and to also reduce the exercise price of the 704,544 warrants from $1.10 to $1.00 per share. In connection with and as additional consideration for the purchase by the third investor, the Company agreed: (i) to issue an additional 163,636 shares of common stock, effectively lowering the purchase price of 1,200,000 shares plus 300,000 warrants previously purchased by the investor from $1.25 to $1.10 per unit, and to also reduce the exercise price of the 300,000 warrants from $1.25 to $1.10 per share; and (ii) to issue an additional 22,500 shares of common stock, effectively lowering the purchase price of 225,000 shares plus 56,250 warrants from $1.10 to $1.00 per unit, and to also reduce the exercise price of the 56,250 warrants from $1.10 to $1.00 per share.
The representations, warranties and covenants contained in the subscription agreements governing the purchases were made solely for the benefit of the parties to the subscription agreements. In addition, such representations, warranties and covenants (i) are intended as a way of allocating the risk between the parties to the subscription agreements and not as statements of fact and (ii) may apply standards of materiality in a way that is different from what may be viewed as material by stockholders of, or other investors in, the Company. Stockholders should not rely on the representations, warranties and covenants in the form of subscription agreement as characterizations of the actual state of facts or condition of the Company or any of its subsidiaries or affiliates as of the date of execution of an agreement with an investor or any previous or subsequent date.
The Company relied on the exemption provided by Rule 506 of Regulation D and Section 4(a)(2) of the Securities Act in connection with the foregoing transactions.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| CYTODYN INC. | ||||||
| Date: January 25, 2022 | By | /s/ Antonio Migliarese | ||||
| Antonio Migliarese Chief Financial Officer | ||||||